The researchers found that when participants took semaglutide, they saw the following improvements: 42 percent lower risk of psychiatric-related hospital care and sick leave 44 percent lower risk of worsening or new depression 38 percent lower risk of worsening or new anxiety 47 percent lower risk of substance use disorder diagnosis or treatment Other GLP-1 drugs showed more variable effects: Liraglutide was linked to a lower risk of worsening depression but not anxiety
It is also believed to stimulate dermatan sulfate, chondroitin sulfate, and decorin, and acts to attract immune and endothelial cells to sites of injury
doi:10.31887/DCNS.2017.19.2/cjones Hoge EA., Pollack MH., Kaufman RE., Zak PJ., Simon NM
W., Feskens, K., Busschbach, J
Retatrutide is an investigational injectable medication developed by Eli Lilly and Company, currently undergoing late-stage clinical evaluation for the treatment of obesity and related metabolic conditions
This is particularly relevant for adults over 40, whose hormonal patterns, sleep architecture, and metabolic rhythms differ meaningfully from the younger populations in most clinical trial protocols